Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02269982 · ClinicalTrials.gov registry record
Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studY
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 120
- Enrollment target
NCT02269982: Completed study, sponsored by Duke University.
NCT02269982 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02269982 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
Study Summary
This study will develop a first-in-man CTC-based molecular taxonomy of CRPC in the context of novel AR-directed therapies, categorize different patterns of resistance in this disease setting, and describe their evolution over time and treatment.
Interventions
- DEVICE AR-v7 assays
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2015-05-14 |
| Est. Completion | 2019-04-30 |
What the finished NCT02269982 record still lists
NCT02269982 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which AR-v7 assays is the first listed.
NCT02269982 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02269982 about?
NCT02269982 is a clinical study titled "Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studY". This study will develop a first-in-man CTC-based molecular taxonomy of CRPC in the context of novel AR-directed therapies, categorize different patterns of resistance in this disease setting, and describe their evolution over time and treatment.
What is the current status of trial NCT02269982?
This trial is currently completed. The enrollment target is 120 participants. The study started on 2015-05-14. Estimated completion is 2019-04-30.
What interventions are being tested in trial NCT02269982?
The interventions under investigation include: AR-v7 assays (DEVICE).
Who is sponsoring clinical trial NCT02269982?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI